Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday

Key Points

• Cardiol Therapeutics is expected to report Q2 2026 results after market close on August 13, with analysts forecasting a loss of $0.09 per share. The company previously reported a $0.07-per-share loss, in line with estimates.
• CRDL shares opened at $1.34, down 1.5%, with a market capitalization of approximately $155 million and a 12-month trading range of $0.88 to $1.71.
• Analyst sentiment is mixed: two analysts rate the stock Buy and one rates it Sell, resulting in a consensus Hold rating and an average price target of $8.50. Institutional investors and hedge funds own 12.49% of the company.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) is expected to post its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors can check the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.07). On average, analysts expect Cardiol Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Cardiol Therapeutics Trading Down 1.5%

Shares of NASDAQ CRDL opened at $1.34 on Thursday. The stock has a market cap of $155.29 million, a PE ratio of -4.79 and a beta of 0.72. Cardiol Therapeutics has a 12-month low of $0.88 and a 12-month high of $1.71. The company has a 50-day moving average of $1.13 and a 200 day moving average of $1.16.

Analyst Upgrades and Downgrades

CRDL has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating on shares of Cardiol Therapeutics in a research report on Tuesday, July 14th. Wall Street Zen lowered Cardiol Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Cardiol Therapeutics in a report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $8.50.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CRDL. Bank of America Corp DE increased its position in shares of Cardiol Therapeutics by 1,983.0% during the 3rd quarter. Bank of America Corp DE now owns 551,053 shares of the company's stock worth $590,000 after purchasing an additional 524,598 shares during the last quarter. Citadel Advisors LLC lifted its position in Cardiol Therapeutics by 1,132.6% in the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company's stock valued at $496,000 after buying an additional 425,862 shares during the last quarter. Two Sigma Investments LP purchased a new position in Cardiol Therapeutics during the third quarter worth about $249,000. Virtu Financial LLC purchased a new position in Cardiol Therapeutics during the third quarter worth about $154,000. Finally, Susquehanna International Group LLP increased its position in shares of Cardiol Therapeutics by 366.5% during the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company's stock valued at $100,000 after acquiring an additional 73,375 shares during the last quarter. 12.49% of the stock is currently owned by institutional investors and hedge funds.

About Cardiol Therapeutics

Cardiol Therapeutics Inc NASDAQ: CRDL is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company's lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source